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Abstract: Tuberculosis remains a disease with an enormous impact on public health worldwide. 
With the continuously increasing epidemic of drug-resistant tuberculosis, new drugs are des-
perately needed. However, even for the treatment of drug-sensitive tuberculosis, new drugs are 
required to shorten the treatment duration and thereby prevent development of drug resistance. 
Within the past ten years, major advances in tuberculosis drug research have been made, leading 
to a considerable number of antimycobacterial compounds which are now in the pipeline. Here 
we discuss a number of these novel promising tuberculosis drugs, as well as the discovery of 
two new potential drug targets for the development of novel effective drugs to curb the tuber-
culosis pandemic, ie, the coronin 1 and protein kinase G pathways. Protein kinase G is secreted 
by mycobacteria and is responsible for blocking lysosomal delivery within the macrophage. 
Coronin 1 is responsible for activating the phosphatase, calcineurin, and thereby preventing 
phagosome-lysosome fusion within the macrophage. Blocking these two pathways may lead to 
rapid killing of mycobacteria.
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Introduction
Mycobacterium tuberculosis continues to be one of the world’s most debilitating and 
deadly pathogens. Tuberculosis accounted for an estimated 1.7 million deaths in 2009, 
and the incidence is higher than ever before, with 9.4 million new cases.1 Efficacious 
drugs exist, but their success in treatment depends on rigid implementation of therapy, 
access to treatment, and adherence over a considerable time span. This has conse-
quences regarding the logistics of tuberculosis control programs, which currently fail 
in many settings in the view of the human immunodeficiency virus (HIV)/acquired 
immune deficiency syndrome copandemic. There are still sizeable populations, espe-
cially in sub-Saharan Africa, which have no access to tuberculosis control through 
the Directly Observed Treatment Short course (DOTS) strategy of the World Health 
Organization. In addition to the urgent need for novel drugs, DOTS coverage should 
be increased further to reduce ongoing transmission.2
Although tuberculosis drug research over the past 10 years has led to the development 
of a few novel agents which are currently in different stages of clinical evaluation, the 
preceding 30 years had been painfully silent in the field of tuberculosis drug research. 
The rise in drug resistance among M. tuberculosis strains has become a severe threat to 
public health on a global scale. With an estimated 440,000 cases of multidrug-resistant 
tuberculosis (defined as Mycobacterium tuberculosis resistance to at least rifampicin 
and isoniazid) and extensively drug-resistant tuberculosis (defined as multidrug-resistant 
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tuberculosis plus resistance to a fluoroquinolone and at least 
one second-line injectable agent, ie, amikacin, kanamycin, 
and/or capreomycin) now being reported in 58 different 
countries, the epidemic is ever increasing.3
Although mortality rates for extensively drug-resistant 
tuberculosis have now been reduced from the initially 
reported nearly 100%4 to approximately 45%,5 it remains a 
challenge to treat infected individuals because of the long 
treatment duration required and inevitable usage of sub-
stances of high cost and with unfavorable safety profiles. In 
HIV-positive patients in Southern Africa, at least 50% of all 
adults have been documented as suffering from tuberculosis.6 
When looking at coinfections in confirmed tuberculosis cases 
with HIV, these reached up to 95% in the Johannesburg 
setting, which is the highest coinfection rate ever described 
to date in the literature.7 All this puts additional pressure 
on the need to develop more effective strategies to curb the 
tuberculosis pandemic, and in particular, this includes novel, 
more effective, and well tolerated drugs.
Apart from the need for new drugs to treat drug-resistant 
tuberculosis, several challenges are faced, even for drug-
susceptible tuberculosis. Drug-susceptible tuberculosis still 
needs to be treated with a regimen containing at least four 
different drugs, and treatment should be continued for at 
least 6 months. Compliance and adherence would increase 
with shorter treatment courses containing fewer drugs. 
Furthermore, there are important interactions with the rifamy-
cins and the most widely used antiretroviral drugs for HIV, 
making coinfection with tuberculosis and HIV complicated 
to treat and creating a need for new drugs which lack these 
interactions. Short and safe treatment regimens for latent 
tuberculosis (with an estimated 2 billion people living with 
latent tuberculosis serving as a continuous reservoir for new 
active cases) still need to be developed.
In this review, we briefly outline the problem of 
multidrug-resistant and extensively drug-resistant tuber-
culosis, give an overview of novel regimens currently in 
clinical evaluation, describe the mechanisms of survival of 
M. tuberculosis in infected hosts, and propose avenues cur-
rently being addressed in the authors’ laboratories that may 
contribute towards the development of therapies targeting 
drug-susceptible, multidrug-resistant, and extensively drug-
resistant tuberculosis.
Multidrug and extensively  
drug-resistant tuberculosis
Control programs are often overburdened in highly endemic 
countries, giving rise to M. tuberculosis drug resistance due 
to a range of predisposing factors and circumstances.8 The 
emergence of multidrug-resistant and extensively drug-
resistant tuberculosis strains has been prominent in parts of 
the former USSR, particularly the Baltic republics and some 
Western megametropolitan areas such as New York City, as 
well as India, China, and the African continent, with a focus 
on its south, as highlighted by the first described outbreak 
of an extensively drug-resistant strain of M. tuberculosis in 
KwaZulu Natal, with excessive mortality.4
The mechanisms involved in the development of mul-
tidrug resistant and extensively drug-resistant tuberculosis 
are complex and determined by the mycobacterium, the 
host, and iatrogenic factors. Firstly, mycobacteria have a 
high degree of intrinsic resistance to most antibiotics and 
chemotherapeutics due to the low permeability of the myco-
bacterial cell wall.9 Numerous chromosomal mutations have 
been associated with the development of drug resistance 
in tuberculosis.10 One of several host factors predisposing 
to tuberculosis drug resistance is immunosuppression.11 
However, development of drug resistance against tubercu-
losis is mainly associated with intensive drug use and lack 
of compliance with treatment. Epidemics of drug-resistant 
tuberculosis, as for example in South Africa, can be largely 
attributed to poor performance of control programs and low 
cure rates over many years.12
Novel drugs to combat TB
The drugs currently used for tuberculosis were discovered 
before 1970. After that, the world of tuberculosis drug 
research remained silent for over 30 years. Over the past 
decade, drug development efforts have increased, fuelled by 
the upcoming threat of drug resistance and the tuberculosis 
epidemics which are ever increasing, and also influenced by 
the expansion of the HIV pandemic.
At the time of writing, there are currently at least 13 drugs 
in different stages of preclinical or clinical evaluation (http://
www.newtbdrugs.org/pipeline.php) for the treatment of 
tuberculosis (see Table 1).5,13–26 They can be roughly divided 
into three categories, ie, novel drugs, drugs currently licensed 
for other indications but “repurposed” for tuberculosis, 
and the current first-line tuberculosis drugs which are re-
evaluated to optimize their efficacy. There are two main lines 
of development, ie, improving treatment of drug-sensitive 
tuberculosis (cutting down on the required duration of 
therapy) to yield higher cure rates and curb development of 
resistance, and improving and shortening treatment of drug-
resistant tuberculosis. In the authors’ view, these should not 
be considered as competing but as complementary areas of 
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interest because both need to be addressed in order to turn 
the tide against tuberculosis at the “drug front”.
Although compared with ten years ago many promising 
new drugs are being developed, a further understanding 
of the pathogenesis of tuberculosis, latent infection, and 
development of drug resistance is needed in order to identify 
novel drug targets which may pave the way for further drug 
development.
Mechanisms of survival of  
M. tuberculosis within infected hosts
To be able to interfere with the persistence mechanisms 
developed by M. tuberculosis, it is important to understand 
the virulence mechanisms that the organism utilizes to 
establish itself within its human host. After entry into the 
host organism via the respiratory tract, mycobacteria are 
phagocytosed by macrophages and resist lysosomal degra-
dation, thus allowing them to survive as well as to multiply 
within macrophage phagosomes, thereby circumventing 
the normal host response that would normally result in 
lysosomal degradation of the bacilli.27–29 Subsequently, 
M. tuberculosis uses an array of strategies to remain 
viable within an infected host, including escape into the 
cytosol,30 residence outside macrophages, for example, 
within caseous regions of granulomas,31,32 modulation of 
nitric and oxygen stress33 and regulation of autophagic 
processes.34 In fact, M. tuberculosis, as one of the most 
successful pathogens known, has evolved an array of 
mechanisms to counteract the host immune response at 
virtually every imaginable level.35
A comprehensive discussion of these mechanisms falls well 
beyond the scope of this paper, and the reader is referred to recent 
excellent review articles. Here, we focus on those mechanisms 
that M. tuberculosis has evolved to modulate intraphagosomal 
survival, and given the attenuation of M. tuberculosis strains 
that have lost the capacity to survive within macrophages,36,37 
or even reside within the macrophage cytosol,30 targeting 
intramacrophage survival mechanisms is likely to contribute 
to the control of M. tuberculosis proliferation.
Escape of mycobacteria from host defenses may also 
allow reactivation of tuberculosis in adults. This occurs 
when so-called dormant foci left in the host after a primary 
infection become reactivated.38 Reactivation can occur when 
the host immune system fails to control bacterial growth or 
when the immune system is deteriorating, eg, as a result of 
malnutrition, overcrowding, or stress,39 resulting in uncon-
trolled bacterial growth and death of the host.
Because of the important role of the macrophage phago-
some as an escape site for M. tuberculosis, substantial efforts 
have been directed at defining the biology of mycobacterial 
entry and survival inside phagosomes. The mycobacterial 
phagosome, because it is derived from the plasma mem-
brane, has many features in common with the membrane.40–43 
However, in contrast with normal phagocytosis, in which 
phagosomal content is delivered to lysosomes either by matu-
ration or through vesicular traffic of intermediate vesicles, 
mycobacteria actively resist lysosomal delivery.27
Several strategies have been used to define mycobacterial 
virulence factors. These have included characterization of 
the erp gene product through generation of mutant strains,44 
Table 1 Overview of antituberculous drugs currently in different stages of clinical development, the chemical class to which they 
belong, and their mechanism of action




(Tibotec BVBA, Beerse, Belgium)
Diaryquinolones PPI blocking mycobacterial ATP synthase II, III
SQ10923 
(Sequella, NIH, Rockville, MD)
Ethylenediamine Inhibition of cell wall synthesis II
Delamanid (OPC-67683)13,21,25 
(Otsuka Pharmaceuticals Inc, Tokyo, Japan)
Nitroimidazoles Inhibition of cell wall mycolic acid biosynthesis III
PA-82420 
(TB Alliance, New York, NY)
Nitroimidazoles Inhibition of cell wall mycolic acid biosynthesis II
Licensed drugs being repurposed for use in tuberculosis
Moxifloxacin5,24,26 Fluoroquinolones Inhibition of DNA replication and transcription III
Gatifloxacin24,26 Fluoroquinolones Inhibition of DNA replication and transcription III
Linezolid15,16 Oxalidinones Inhibition of protein synthesis II
Tuberculosis drugs re-evaluated to optimize efficacy
Rifapentin14,17 Rifamycins Inhibition of DNA-dependent RNA synthesis II, III
Note: References mentioned are clinical trials reporting on efficacy, safety, and pharmacokinetics.
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proteins with a regulatory function, such as sigma factors 
as well as enzymes that function in different mycobacterial 
biochemical pathways, such as isocitrate lyase and glutamine 
synthetase.45–48 On the host side, the recently identified 
interferon-gamma-induced LRG-47 gene was suggested to act 
as a vacuolar trafficking regulator necessary for the control 
of intracellular mycobacterial growth.49
Different signaling pathways have been implicated in the 
survival mechanisms for pathogenic mycobacteria, including 
modulation of Ca2 signaling upon entry50 and regulation 
of phagosome-lysosome fusion through phosphorylation/
dephosphorylation.51
Thus, M. tuberculosis uses multiple strategies to cir-
cumvent innate host immunity to infections. This unique 
capacity of M. tuberculosis to remain viable within the 
mycobacterial phagosome by avoiding lysosomal delivery 
within macrophages may be important for its capacity not 
only to survive for prolonged periods but also to cause severe 
disease and death in infected individuals.
Discovery of novel drug targets  
to block survival of M. tuberculosis
The capacity of M. tuberculosis to cause disease lies in its 
ability to avoid destruction within those cells that normally 
destroy all incoming bacteria, namely the macrophages. 
While bacteria are normally internalized into phagosomes 
from which they are transported to lysosomes where they 
are destroyed, M. tuberculosis actively blocks their transfer 
to lysosomes, allowing them to survive for prolonged times 
within phagosomes. A long-term interest in the mechanisms 
utilized by M. tuberculosis to circumvent host resistance, 
thereby allowing these bacteria to proliferate and cause dis-
ease, has been maintained in the laboratories of RJ and JP.
Recent work has unraveled two pathways via which 
M. tuberculosis manages to survive within host cells. One 
mechanism relies on the secretion of a eukaryotic-like kinase 
by M. tuberculosis, ie, protein kinase G, the expression of 
which is essential to block lysosomal delivery.52,53 A second 
strategy relies on the retention of a host molecule, coronin 1, 
at the mycobacterial phagosome that is responsible for acti-
vating the phosphatase, calcineurin.54,55 Interestingly, current 
work suggests that targeting of protein kinase G as well as the 
coronin 1/calcineurin pathway may result in rapid killing of 
internalized mycobacteria. Whether or not inhibition of these 
recently discovered pathways would block survival and pro-
liferation of multidrug-resistant and extensively drug-resistant 
strains of M. tuberculosis remains to be analyzed.
Targeting protein kinase G to 
promote killing of M. tuberculosis
Protein kinase G was discovered in a search for mycobac-
terial factors that promote survival of pathogenic myco-
bacteria within host macrophages. Protein kinase G is a 
eukaryotic-like serine/threonine protein kinase that is not 
required for mycobacterial growth per se but is essential 
for its survival within host macrophages (Figure 1), and 
has been discussed in detail elsewhere.53,56 Protein kinase 
G is one of the 11 serine/threonine protein kinases found in 









Figure 1 Protein kinase G-mediated and coronin 1-mediated survival within host macrophages.
© Copyright National Academy of Sciences, USA. Reproduced with permission from Scherr N, Honnappa S, Kunz G, et al. Structural basis for the specific inhibition of protein 
kinase G, a virulence factor of Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 2007;104:12151–12156.52
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M. tuberculosis, and the only soluble kinase maintained in 
the genome of M. leprae that is believed to have retained the 
minimal set of genes essential for virulence.57 The presence 
of domains typically found in proteins from eukaryotic spe-
cies as well as the finding that protein kinase G is dispens-
able for in vitro growth of M. tuberculosis56,58 suggests that 
protein kinase G has arrived in the M. tuberculosis genome 
through horizontal gene transfer and has been maintained 
as a virulence factor important for its survival inside the 
eukaryotic host.59
Importantly, mycobacteria overexpressing a kinase-dead 
mutant of protein kinase G are rapidly transferred to lyso-
somes and killed, thus demonstrating that protein kinase G 
activity is crucial for mycobacterial survival. The fact that 
protein kinase G is translocated into the host cytosol suggests 
that compounds aimed at blocking protein kinase G activity 
do not require translocation across the only slightly perme-
able mycobacterial cell wall.53
Together, these findings make protein kinase G an attrac-
tive and promising drug candidate. Indeed, blocking protein 
kinase G activity by a specific small molecular weight inhibi-
tor, ie, the tetrahydrobenzothiophene, AX20017, results in 
rapid transfer of mycobacteria to lysosomes and killing of 
intracellularly residing bacilli.53,56 Furthermore, detailed 
biochemical analysis of the domains of protein kinase G 
has revealed several key residues that are crucial for both its 
in vitro kinase activity as well as the virulence function of 
protein kinase G within infected macrophages.60,61
Two recently obtained sets of results have contributed to 
the validation of protein kinase G as a potential drug target. 
First, infecting mice with M. tuberculosis lacking protein 
kinase G resulted in dramatically prolonged survival of 
infected mice (mean survival time prolonged from 12 weeks 
to 50 weeks, unpublished data). This suggests that targeting 
protein kinase G in vivo may significantly alter the outcome 
of infection with M. tuberculosis. Second, we have recently 
obtained the x-ray structure of protein kinase G complexed 
with its inhibitor (Figure 2). The structure shows that protein 
kinase G contains a unique ATP-binding pocket that is dif-
ferent from any of the 491 human kinases known; in fact, a 
potent protein kinase G inhibitor showed virtually no activity 
when tested against a panel of 28 different kinases originat-
ing from the six major kinase groups. Thus, the structure of 
protein kinase G was revealed to be distinct from the host cell 
kinases, allowing its efficient targeting without blocking host 
cell kinases.52 Interestingly, docking studies using the tridi-
mensional structure of protein kinase G identified potential 
novel inhibitors of the withanolide compound class.62
These preliminary findings suggest that targeting protein 
kinase G may enable inhibition of M. tuberculosis growth 
within host cells by allowing the macrophages to carry out 
their natural innate immune function, namely, shuttling 
M. tuberculosis to degradative lysosomes.
Inhibition of coronin 1-mediated 
signaling to block resistant  
M. tuberculosis
In 1999, coronin 1, also known as tryptophan aspartate-con-
taining coat protein or p57,63 was described as a protein that 
was actively retained in mycobacterial phagosomes, and was 
predicted to be involved in blocking the delivery of pathogenic 
mycobacteria to lysosomes (Figure 1).54 This suggested an essen-
tial role for coronin 1 in protecting the mycobacterial phagosome 
from fusion with lysosomes,54,64 confirmed subsequently using 
siRNA-mediated knockdown of coronin 1.65–67 Moreover, myco-
bacteria are effectively destroyed within Kupffer cells, the major 
macrophages in the liver that do not express coronin 1.54
How coronin 1 mediates the survival of pathogenic 
mycobacteria has been revealed recently by generating 
mice lacking coronin 1. It turns out that while mice lack-
ing coronin 1 are perfectly healthy, coronin 1 is required for 
activation of the Ca2-dependent phosphatase, calcineurin.55 
In wild-type macrophages, upon internalization of mycobac-




Figure 2 Structure of protein kinase G with inhibitor.
Note: Inset: protein kinase G crystal.
© Copyright National Academy of Sciences, USA. Reproduced with permission 
from Scherr N, Honnappa S, Kunz G, et al. Structural basis for the specific inhibition 
of protein kinase G, a virulence factor of Mycobacterium tuberculosis. Proc Natl Acad 
Sci U S A. 2007;104:12151–12156.52 




Novel drugs for tuberculosis
Drug Design, Development and Therapy 2012:6
phagosome-lysosome fusion by an as yet unknown mechanism 
and allowing survival of mycobacteria. In the absence of 
coronin 1, calcineurin activation does not occur, resulting in 
phagosome-lysosome fusion and intracellular killing of the 
internalized mycobacteria. Strikingly, genetic depletion of 
coronin 1 can be phenocopied by addition of the calcineurin 
inhibitors, cyclosporin A and FK506 (Figure 3). Thus, it appears 
that coronin 1 has evolved to activate Ca2-dependent signaling 
reactions in macrophages, thereby promoting the survival of 
pathogenic mycobacteria.55
These results suggest that blocking the coronin 1 signaling 
pathway may allow intracellular killing of M. tuberculosis. 
Preliminary results indeed suggest that in vivo administration 
of calcineurin inhibitors allows rerouting of M. tuberculosis 
inside macrophages.55 Because this newly discovered path-
way is unlikely to be related to any of the mechanisms that 
are currently targeted by available tuberculosis drugs, we 
anticipate that blockers of the coronin 1 pathway may be 
useful for treatment of drug-resistant tuberculosis.
Therapeutic potential of agents 
blocking protein kinase G and 
coronin 1
Preliminary data have shown that blocking either the protein 
kinase G or the coronin 1 pathway may be highly specific for 
inhibiting growth of M. tuberculosis inside macrophages with-
out affecting host functioning. For protein kinase G inhibition, 
a potent inhibitor of protein kinase G53 was not active against 
a panel of 28 human kinases that were selected to represent 
the entire human kinome.52 In addition, when macrophages 
were exposed to high concentrations of these inhibitors, all 
measurable cellular functions appeared normal.
With regard to coronin 1 inhibition, the clearest indica-
tion that coronin 1 can be blocked without obvious adverse 
effects is the phenotype of coronin 1-deficient mice. These 
mice develop normally, are healthy, and show no obvious 
phenotype.55 In addition, the inhibitory protocol that we 
have developed to block the coronin 1-signaling pathway is 
based on use of cyclosporin A and/or FK506, both of which 
are drugs approved for use in humans.68,69
Conclusion
It is reassuring that after many years, a tuberculosis drug 
pipeline is now developing. Moreover, several novel path-
ways essential for M. tuberculosis survival are currently 
being explored, including the protein kinase G and coronin 
1 pathways, which have potential to serve as novel drug tar-
gets for treatment of both drug-sensitive and drug-resistant 
tuberculosis. Whilst pressing on with the development of 
drugs and optimized combination and usage of existing 
drugs at the “outcome” end of the pipeline, concerted effort 
is needed to expand further the portfolio of novel drug targets 
and to identify novel leads.
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